Treatment of Protein S Deficiency Following Acute Venous Thromboembolism
Protein S deficiency carries an elevated risk of venous thromboembolism (VTE). When an acute VTE event occurs — such as deep vein thrombosis or pulmonary embolism — a structured anticoagulation protocol is indicated, beginning with exclusion of high-risk antiphospholipid syndrome.
Clinical Scenario
This protocol applies to patients with confirmed Protein S deficiency who present with or develop an acute VTE event. The clinical goals are deep vein recanalization and resolution or meaningful improvement of embolism symptoms and signs, assessed at defined follow-up intervals of 3 and 6 months.
Treatment Approach — Partial Overview
After ruling out high-risk antiphospholipid syndrome, the protocol begins with parenteral anticoagulation adjusted to clinical conditions. This is followed by a transition to oral anticoagulant therapy, with the dose subsequently re-evaluated based on clinical response at scheduled follow-up assessments.
Full agent selection, sequencing, and dose-modification criteria available in the complete protocol →
References
DOI: 10.1186/s12959-026-00861-w
- Nineteen patients, who had an acute clinical event (VTE) right before or during the observation at the Center, underwent treatment with Enoxaparin (range 4000–16000 IU/die) or Fondaparinux (range 2.5–7.5 mg/die) according to the clinical conditions, after ruling out high-risk antiphospholipid syndrome.
- The duration of this therapy was 3 to 6 months because other professionals had prescribed it.
- Subsequently, the majority of these patients underwent a full-dose of doac therapy (apixaban 5 mg BID or rivaroxaban 20 mg once a day).
- The time spent in full dose was of 12 months, on average.
- At 3 and 6 months, when deep vein recanalization occurred or embolism symptoms/signs improved or disappeared, apixaban was reduced from 5 to 2.5 mg BID and rivaroxaban from 20 to 10 mg/once a day, monitoring compliance with plasma levels of doac.
View source ↗